OVERVIEW
Precision medicine emerged to prominence over the last decade to improve medical outcomes, allowing for personalized cancer treatments. The speed of scientific breakthroughs in precision medicine is leading to groundbreaking therapies. Novel Artificial Intelligence (AI) engines can potentially help to identify patterns and allow teams to uncover innovative strategies for specific cancers and individual patient populations. Today more than ever before, physician-scientists working with patients need real-time information aimed at creating an improved, value-based survivorship.

The first Miami Precision Medicine (MPM) international conference will bring together diverse experts in the field to share their knowledge and approaches in moving precision medicine towards routine practice. The course will examine the treatment landscape for various cancer types through an interdisciplinary molecular tumor board case discussion that will cover the role of precision medicine in selecting targeted treatments as well as present relevant precision medicine clinical trials.

Patients and advocacy groups will have an opportunity to share their insight, learn about promising clinical trials and partner with physicians to develop new strategies tailored to their specific needs.

LEARNING OBJECTIVES
At the conclusion of this activity, participants will be able to:

• Interpret next generation sequencing (NGS) results
• Interpret results of a liquid biopsy (ctDNA)
• Describe common molecular alterations and the role of molecular diagnostic tests in different cancer types
• Distinguish actionable vs. non-actionable genetic alterations
• Summarize recent and emerging data from key trials in the following areas: immunotherapeutic malignancies (melanoma), pediatric cancers, neuro-oncology, breast cancer, lung cancer, sarcoma, and gynecologic malignancies
• Translate current knowledge on actionable molecular alterations into value-based therapeutic strategies
• Summarize role of biomarkers in selection of targeted therapies
• Recognize the emerging role of Artificial Intelligence in precision medicine
• List precision medicine clinical trials available and their preliminary promising results
• Implement strategies designed to improve the quality of cancer care, address barriers to optimal care and enhance the patient experience
• Identify scientific advances in the field of cancer biology
• Develop collaborations that will lead to improved clinical trial recruitment and success of the participation
• Interact with patients and patient advocacy groups to promote access to molecularly-driven therapies and available clinical trials
• Facilitate patient/physician-focused interaction and an understanding of survivorship challenges in the era of precision medicine

DISCLOSURE AND CONFLICT OF INTEREST RESOLUTION
The University of Miami School of Medicine designates this live activity for a maximum of 7.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in this activity.

ACCREDITATION
The University of Miami School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

LEARNING OBJECTIVES
At the conclusion of this activity, participants will be able to:

• Interpret next generation sequencing (NGS) results
• Interpret results of a liquid biopsy (ctDNA)
• Describe common molecular alterations and the role of molecular diagnostic tests in different cancer types
• Distinguish actionable vs. non-actionable genetic alterations
• Summarize recent and emerging data from key trials in the following areas: immunotherapeutic malignancies (melanoma), pediatric cancers, neuro-oncology, breast cancer, lung cancer, sarcoma, and gynecologic malignancies
• Translate current knowledge on actionable molecular alterations into value-based therapeutic strategies
• Summarize role of biomarkers in selection of targeted therapies
• Recognize the emerging role of Artificial Intelligence in precision medicine
• List precision medicine clinical trials available and their preliminary promising results
• Implement strategies designed to improve the quality of cancer care, address barriers to optimal care and enhance the patient experience
• Identify scientific advances in the field of cancer biology
• Develop collaborations that will lead to improved clinical trial recruitment and success of the participation
• Interact with patients and patient advocacy groups to promote access to molecularly-driven therapies and available clinical trials
• Facilitate patient/physician-focused interaction and an understanding of survivorship challenges in the era of precision medicine

DISCLOSURE AND CONFLICT OF INTEREST RESOLUTION
The University of Miami School of Medicine designates this live activity for a maximum of 7.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in this activity.

ACCREDITATION
The University of Miami School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
OVERVIEW
Precision medicine emerged to prominence over the last decade to major impact on outcomes, allowing for personalized cancer treatments. The speed of scientific breakthroughs in precision medicine is leading to groundbreaking therapies. Novel Artificial Intelligence (AI) engines can potentially help to identify patterns and allow teams to uncover innovative strategies for specific cancers and individual patient populations. Today more than ever before, physician-scientists working with patients need real-time information aimed at creating an improved, value-based survivorship.

The first Miami Precision Medicine (MPM) international conference will bring together diverse experts in the field to share their knowledge and approaches in moving precision medicine toward routine practice. The course will examine the treatment landscape for various cancer types, the role of next-generation sequencing, and how it has shaped clinical practice. The interdisciplinary molecular tumor board case discussion will illustrate the role of genomic alterations in selecting targeted treatments as well as present relevant precision medicine clinical trials.

Patients and advocacy groups will have an opportunity to share their insight, learn about promising clinical trials and partner with physicians to develop new strategies tailored to their specific needs.

TARGET AUDIENCE
The educational activity is intended for adult and pediatric medical hematologists and oncologists, surgical and radiation oncologists, gynecologic oncologists, pharmacists, primary care physicians, physician assistants, advanced registered nurse practitioners, nurses, research members, residents, fellows, patients and patient-advocacy groups as well as other allied health professionals.

CREDIT DESIGNATION
The University of Miami Leonard M. Miller School of Medicine designates this live activity for a maximum of 7.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

LEARNING OBJECTIVES
At the conclusion of this activity, participants will be able to:
• Interpret next generation sequencing (NGS) results
• Interpret results of a liquid biopsy (ctDNA)
• Describe common molecular alterations and the role of molecular diagnostic tests in different cancer types
• Distinguish actionable vs. non-actionable genetic alterations

TARGET AUDIENCE
The educational activity is intended for adult and pediatric medical hematologists and oncologists, surgical and radiation oncologists, gynecologic oncologists, pharmacists, primary care physicians, physician assistants, advanced registered nurse practitioners, nurses, research members, residents, fellows, patients and patient-advocacy groups as well as other allied health professionals.

CREDIT DESIGNATION
The University of Miami Leonard M. Miller School of Medicine designates this live activity for a maximum of 7.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ACCREDITATION
The University of Miami CME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AGENDA
SUNDAY, APRIL 26, 2020

10:45 – 11:30 AM
Welcome and Opening Remarks

11:40 – 12:00 PM
Pre-Session Survey

12:00 – 12:30 PM
Continental Breakfast and Visit Exhibits

1:00 – 12:00 PM
The全景 in Drug Development: Key Drivers of Commercial Success in Oncology

12:45 – 1:45 PM
Lunch – Faculty and Attendees

1:45 – 2:20 PM
Precise Medicine in Treating GI Cancers

2:20 – 3:20 PM
Current Use and Future Applications of Precise Medicine in Treating GI Cancers

3:20 – 4:00 PM
Precision Medicine in Lung Cancer

4:00 – 5:00 PM
Targeted Therapies in Acute Myeloid Leukemia

5:00 – 6:00 PM
Research and Development in Emerging Fields of Precision Medicine

6:00 – 7:00 PM
Coffee Break and Visit Exhibits

REGISTRATION FORM
To register, please visit www.cme.med.miami.edu or complete this form and email to: dwielch@miami.edu

First Name __________________ Last Name ____________________ Degree (MD, DO, PhD, ARNP, etc.) ______________

REGISTRATION CANCELLATION POLICY
Registrants will be refunded only if notification is received in writing. To receive a full refund, please submit your written request to dwielch@miami.edu prior to April 1, 2020. After this date, only partial refunds will be made (50% of the total paid). Note there will be no refunds after April 15, 2020. In cases where a course is cancelled due to insufficient registrations, a full tuition refund will be made.

SERVICES FOR THE DISABLED
Please contact the Division of CME prior to March 31, 2020 should you have any special needs that may require additional considerations. A CME Curriculum Director will contact you to arrange these special requirements.

For more information, contact
Division of Continuing Medical Education
Carmen Calle, MD
CME Program Manager
Fax: (305) 243-6775

Please contact the Division of CME prior to March 31, 2020 should you have any special needs that may require additional considerations. A CME Curriculum Director will contact you to arrange these special requirements.

For more information, contact
Division of Continuing Medical Education
Carmen Calle, MD
CME Program Manager
Fax: (305) 243-6775

REGISTRATION FORM
To register, please visit www.cme.med.miami.edu or complete this form and email to: dwielch@miami.edu

First Name __________________ Last Name ____________________ Degree (MD, DO, PhD, ARNP, etc.) ______________

REGISTRATION CANCELLATION POLICY
Registrants will be refunded only if notification is received in writing. To receive a full refund, please submit your written request to dwielch@miami.edu prior to April 1, 2020. After this date, only partial refunds will be made (50% of the total paid). Note there will be no refunds after April 15, 2020. In cases where a course is cancelled due to insufficient registrations, a full tuition refund will be made.

SERVICES FOR THE DISABLED
Please contact the Division of CME prior to March 31, 2020 should you have any special needs that may require additional considerations. A CME Curriculum Director will contact you to arrange these special requirements.

For more information, contact
Division of Continuing Medical Education
Carmen Calle, MD
CME Program Manager
Fax: (305) 243-6775

Please contact the Division of CME prior to March 31, 2020 should you have any special needs that may require additional considerations. A CME Curriculum Director will contact you to arrange these special requirements.

For more information, contact
Division of Continuing Medical Education
Carmen Calle, MD
CME Program Manager
Fax: (305) 243-6775

Please contact the Division of CME prior to March 31, 2020 should you have any special needs that may require additional considerations. A CME Curriculum Director will contact you to arrange these special requirements.

For more information, contact
Division of Continuing Medical Education
Carmen Calle, MD
CME Program Manager
Fax: (305) 243-6775

Please contact the Division of CME prior to March 31, 2020 should you have any special needs that may require additional considerations. A CME Curriculum Director will contact you to arrange these special requirements.

For more information, contact
Division of Continuing Medical Education
Carmen Calle, MD
CME Program Manager
Fax: (305) 243-6775

Please contact the Division of CME prior to March 31, 2020 should you have any special needs that may require additional considerations. A CME Curriculum Director will contact you to arrange these special requirements.

For more information, contact
Division of Continuing Medical Education
Carmen Calle, MD
CME Program Manager
Fax: (305) 243-6775

Please contact the Division of CME prior to March 31, 2020 should you have any special needs that may require additional considerations. A CME Curriculum Director will contact you to arrange these special requirements.

For more information, contact
Division of Continuing Medical Education
Carmen Calle, MD
CME Program Manager
Fax: (305) 243-6775

Please contact the Division of CME prior to March 31, 2020 should you have any special needs that may require additional considerations. A CME Curriculum Director will contact you to arrange these special requirements.

For more information, contact
Division of Continuing Medical Education
Carmen Calle, MD
CME Program Manager
Fax: (305) 243-6775

Please contact the Division of CME prior to March 31, 2020 should you have any special needs that may require additional considerations. A CME Curriculum Director will contact you to arrange these special requirements.
OVERVIEW

Precision medicine emerged to prominence over the last decade, leading to major impacts on outcomes, allowing for personalized cancer treatments. The speed of scientific breakthroughs in precision medicine is leading to groundbreaking therapies. Novel Artificial Intelligence (AI) engines can potentially help to identify patterns and allow teams to uncover innovative strategies for specific cancers and individual patient populations. Today more than ever before, physician-scientists working with patients need real-time information aimed at creating an improved, value-based survivorship.

The first Miami Precision Medicine (MPM) international conference will bring together diverse experts in the field to share their knowledge and approaches in moving precision medicine toward routine practice. The course will explore the treatment landscape for various cancer types and provide a snapshot of some of the most cutting-edge innovations in precision medicine. This multidisciplinary two-day format will ensure that medical professionals of all specialties are provided with the best possible treatment options.

TARGET AUDIENCE

The educational activity is intended for adult and pediatric medical hematologists and oncologists, surgical and radiation oncologists, gynecologic oncologists, pharmacists, primary care physicians, physician assistants, advanced registered nurse practitioners, nurses, research members, residents, fellows, patients and patient-advocacy groups as well as other allied health professionals.

LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:

- Interpret next generation sequencing (NGS) results
- Interpret results of a liquid biopsy (ctDNA)
- Describe common molecular alterations and the role of molecular diagnostic tests in different cancer types
- Distil actionable vs non-actionable genetic alterations
- Summarize recent and emerging data from key trials and genomic alterations
- Use the following areas: hemato-oncological malignancies (acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndromes), breast cancer, prostate cancer, gastrointestinal cancer, sarcoma, lung cancer, melanoma, gynecological malignancies
- Translate current knowledge on actionable molecular alterations into value-based therapeutic strategies
- Summarize role of biomarkers in selection of targeted therapies
- Recognize the emerging role of Artificial Intelligence in precision medicine
- List precision medicine clinical trials available and their preliminary promising results
- Implement strategies designed to improve the quality of cancer care, reduce barriers to optimal care and enhance the patient experience
- Identify scientific advances in the field of cancer biology and tumor pathogenesis
- Develop collaborations that will lead to improved clinical outcomes and societal impact
- Engage with scientific experts and promote access to molecularly-driven therapies and available clinical trials
- Facilitate patient-physician interaction and an understanding of survivorship challenges in the era of precision medicine

DISCLOSURE AND CONFLICT OF INTEREST RESOLUTION

The University of Miami, Miller School of Medicine designates this live activity for a maximum of 7.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ACREDITATION

The University of Miami, Miller School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION

The University of Miami, Miller School of Medicine designates this live activity for a maximum of 7.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.